Comprehensive VAERS Analysis Confirms Safety Profile of Pneumococcal Vaccines Across Multiple Formulations
Key Insights
A comprehensive analysis of 157,244 patients receiving pneumococcal vaccines found that 81.84% of adverse events were non-serious, with the most common reactions being injection site erythema, swelling, and pain.
The study identified 929 significant safety signals across multiple pneumococcal vaccine formulations using four disproportionality analysis methods, with 77.11% of adverse events occurring within 30 days post-vaccination.
This first-of-its-kind pharmacovigilance study integrating safety data across all pneumococcal vaccines in the U.S. VAERS database provides evidence-based risk stratification to inform clinical vaccination strategies.
A landmark pharmacovigilance study analyzing over three decades of post-marketing surveillance data has confirmed the established safety profile of pneumococcal vaccines, providing the most comprehensive assessment to date of adverse events across multiple vaccine formulations. The research, published in Frontiers in Cellular and Infection Microbiology, represents the first study to systematically integrate safety signals across all pneumococcal vaccines using the U.S. Vaccine Adverse Event Reporting System (VAERS) database.
Comprehensive Safety Analysis Reveals Predominantly Mild Reactions
The study analyzed 157,244 individuals who received pneumococcal vaccines between January 1990 and March 2025, documenting 632,481 adverse events (AEs). The analysis revealed that 81.84% of reported adverse events were classified as non-serious, while 18.16% constituted serious AEs. Among patients experiencing adverse events, complete recovery was the most frequent clinical outcome at 44.20%, followed by hospitalization attributable to the AEs at 14.94%.
The temporal analysis demonstrated that 77.11% of patients developed adverse events within 0-30 days post-vaccination, with a mean time to onset of 4.20 days. This finding provides critical insights for healthcare providers regarding the expected timeframe for monitoring patients following pneumococcal vaccination.
Injection Site Reactions Dominate Safety Profile
Using four complementary disproportionality analysis methods—Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS)—researchers identified 929 positive safety signals across 24 system organ classes.
The five most frequent adverse event signals were injection site erythema (24,675 cases, ROR = 4.24), injection site swelling (17,938 cases, ROR = 4.19), injection site pain (17,827 cases, ROR = 2.75), erythema (17,778 cases, ROR = 3.99), and injection site warmth (9,224 cases, ROR = 3.63). These findings align with pre-licensure study observations and previous VAERS safety assessments.
Vaccine Utilization Patterns Reflect Clinical Practice
Among the 158,778 doses of pneumococcal vaccines administered, nearly half were 23-valent polysaccharide vaccine (PPSV) at 48.92%, while PCV13 was the most frequently used conjugate vaccine at 27.57%. The analysis showed that newer formulations such as PCV15 (0.76%) and PCV20 (3.10%) had limited representation, likely reflecting their recent introduction and phased implementation in vaccination programs.
Manufacturer data highlighted the dominance of Pfizer/Wyeth (50.92%) and Merck & Co. (43.36%) as primary producers of conjugate and polysaccharide vaccines, respectively. The most commonly administered vaccine was PNEUMOVAX (search) (42.44%), manufactured by Merck & Co., Inc.
Designated Medical Events Screening Identifies Rare Serious Events
The study employed the European Medicines Agency's Designated Medical Events (DME) list to screen for intrinsically severe conditions with frequent associations to medicinal products. Of 51 DME-associated signals identified, 8 positive signals were confirmed across 4 system organ classes. The most frequent DME signals were erythema multiforme (398 cases) and hemolytic anemia (45 cases), while the most robust signals were product contamination microbial (ROR = 11.25) and intestinal perforation (ROR = 3.99).
Notably, among all documented serious adverse events, only 116 cases of immune system disorders were reported, representing a relatively small proportion. All four disproportionality analysis metrics demonstrated non-significant signals for these immune-related events, indicating no statistically detectable safety concern.
Study Limitations and Clinical Implications
The researchers acknowledged several limitations inherent to the VAERS system, including underreporting, variable report quality, and the absence of denominator data for calculating true incidence rates. The lack of exposure denominators prevents extrapolation to estimate actual event frequency or risk in the vaccinated population. Additionally, dose sequence information was missing in 41.45% of reports, precluding meaningful dose-stratified analysis of injection site symptoms.
Despite these constraints, the study provides valuable insights for clinical practice. The finding that most adverse events are mild, self-limited, and occur within 30 days post-vaccination can inform patient counseling and monitoring protocols. Healthcare providers can use this temporal pattern to guide post-vaccination follow-up strategies and patient education.
Implications for Vaccination Programs
The comprehensive analysis supports the continued use of pneumococcal vaccines across all approved formulations, with the safety profile remaining consistent with pre-licensure expectations. The predominance of local injection site reactions and the low incidence of serious immune-related events provide reassurance for vaccination programs targeting high-risk populations.
The study's findings are particularly relevant given the ongoing evolution of pneumococcal vaccine recommendations, with newer formulations like PCV15 and PCV20 expanding coverage against additional serotypes. As these newer vaccines gain broader adoption, continued post-marketing surveillance will be essential to monitor their safety profiles.
The research emphasizes the critical role of pharmacovigilance systems like VAERS in maintaining public confidence in vaccination programs through transparent safety monitoring. While the system's limitations necessitate cautious interpretation of observed associations, it remains valuable for initial identification of rare safety signals and emerging concerns that may require further investigation through more robust epidemiological studies.